Distinguished in Febrile Neutropenia

Lisa M. Orme

305 Grattan St, 
Melbourne, VIC, AU 
Distinguished in Febrile Neutropenia
305 Grattan St, 
Melbourne, VIC, AU 
OverviewLocationsClinical Research

Overview

Lisa Orme practices in Melbourne, Australia. Ms. Orme is rated as a Distinguished expert by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Febrile Neutropenia, Infantile Neutropenia, Ewing Sarcoma, and Agranulocytosis.

Her clinical research consists of co-authoring 45 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles in the study of Febrile Neutropenia.

Gender
Female

Locations

305 Grattan St, Melbourne, VIC 3000, Australia
Other Locations
50 Flemington Rd, Parkville, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Enrollment Status: Terminated
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

45 Total Publications

A systematic review on the impact of delayed local therapy in patients with Ewing sarcoma of the pelvis.
A systematic review on the impact of delayed local therapy in patients with Ewing sarcoma of the pelvis.
Journal: Journal of cancer research and clinical oncology
Published: July 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Orme's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile